[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR19980065188A - New synthetic intermediates of moussecon and preparation method thereof - Google Patents

New synthetic intermediates of moussecon and preparation method thereof Download PDF

Info

Publication number
KR19980065188A
KR19980065188A KR1019970000043A KR19970000043A KR19980065188A KR 19980065188 A KR19980065188 A KR 19980065188A KR 1019970000043 A KR1019970000043 A KR 1019970000043A KR 19970000043 A KR19970000043 A KR 19970000043A KR 19980065188 A KR19980065188 A KR 19980065188A
Authority
KR
South Korea
Prior art keywords
compound
organic solvent
catalyst
room temperature
tosyl
Prior art date
Application number
KR1019970000043A
Other languages
Korean (ko)
Other versions
KR100226621B1 (en
Inventor
박대규
Original Assignee
박대규
조선무약 합자회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 박대규, 조선무약 합자회사 filed Critical 박대규
Priority to KR1019970000043A priority Critical patent/KR100226621B1/en
Publication of KR19980065188A publication Critical patent/KR19980065188A/en
Application granted granted Critical
Publication of KR100226621B1 publication Critical patent/KR100226621B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

본 발명은, 무스콘(Muscone)의 신규합성중간체 및 그의 제조방법에 관한 것으로, 하기 구조식(I) 또는 (II)를 갖는다.The present invention relates to a novel synthetic intermediate of Muscone and a method for producing the same, and has the following structural formula (I) or (II).

상기 구조식(I) 또는 (II)의 신규화합물이며, 무스콘의 전구물질로서 이들로부터 엘 또는 디-무스콘을 고수율, 고순도로 제조할 수 있는 특장점이 있다.It is a novel compound of the above-mentioned formula (I) or (II), and has the advantage of being able to manufacture L or di-muscon with high yield and high purity from these as precursors of muscon.

Description

무스콘의 신규합성중간체 및 그의 제조방법New synthetic intermediates of moussecon and preparation method thereof

본 발명은 무스콘(Muscone)의 신규합성중간체 및 그의 제조방법에 관한 것으로, 특히 하기 구조식(I)의 엘-3-메칠-시클로펜타데칸-1-온 1,4-디-O-알킬 또는 아릴-2,3-L-스레이톨 케탈과, 구조식(II)의 디-3-메칠-시클로펜타데칸-1-온 1,4-디-O-알킬 또는 아릴-2,3-L-스레이톨 케탈 및 그들의 제조방법에 관한 것이다.The present invention relates to a novel synthetic intermediate of muscone and a method for preparing the same, and in particular, El-3-methyl-cyclopentadecan-1-one 1,4-di-O-alkyl of formula (I) Aryl-2,3-L-stolitol ketal and di-3-methyl-cyclopentadecan-1-one 1,4-di-O-alkyl or aryl-2,3-L-stray of formula (II) It relates to tall ketal and a method for preparing them.

상기 구조식을 갖는 화합물(I),(II)는 엘-3-메칠-시클로펜타데칸-1-온(III, 이하 엘-무스콘 (l-Muscone)이라 함)과, 디-3-메칠-시클로펜타데칸-1-온(IV), 이하 디-무스콘(d-Muscone)이라 함)의 전물질로써 신규 합성중간체이며, 이들은 뇌질환, 심순환계등에 사용되는 의약품 원료로 유용하게 사용될 전망이다.Compounds (I) and (II) having the above structural formula are L-3-methyl-cyclopentadecan-1-one (III, hereinafter referred to as l-Muscone), and di-3-methyl- As a whole substance of cyclopentadecane-1-one (IV), hereinafter referred to as d-Muscone, it is a new synthetic intermediate, which is expected to be useful as a raw material for medicines used in brain disease, cardiovascular system, etc. .

지금까지 화합물(III)과 (IV)를 제조하기 위해 몇가지의 방법들이 알려져 있으나 그 제조방법들의 대부분은 수율이 매우 낮고 제조원가가 고가이거나 반응조건이 까다롭고 복잡하여 공업화 또는 대량생산에는 적합하지 못한 실정이었다.Several methods have been known to prepare compounds (III) and (IV), but most of the production methods are not suitable for industrialization or mass production due to the low yield, high production cost, and difficult and complicated reaction conditions. It was.

(참조 :1Srallberg, S.S. Arkiz. Kemi. 3, 517, 1951,2Nelson, K.A. and Mash, E.A. J. Org, Chem. 51, 2721, 1986,3H.Nohira J. Org. Chem. 52, 1630, 1987,4Tanaka, K. and Uscio, H. J. Chem. Soc. Chem. Commun. 1, 101, 1991)(Reference: 1 Srallberg, SS Arkiz. Kemi. 3, 517, 1951, 2 Nelson, KA and Mash, EAJ Org, Chem. 51, 2721, 1986, 3 H. Nohira J. Org. Chem. 52, 1630, 1987 , 4 Tanaka, K. and Uscio, HJ Chem. Soc.Chem.Commun. 1, 101, 1991)

따라서, 본 발명자는 상기와 같은 종래의 기술상의 문제점을 해결하기 위해 10여년에 걸쳐 연구하여 온 결과 화합물(I),(II)가 화합물(III)과 (IV)를 대량생산할 수 있는 신규 합성중간체로써 유용함을 발견하고 화합물(I),(II) 및 그들의 제조방법을 강구하여 본 발명을 완성하게 되었다.Therefore, the present inventors have studied over 10 years to solve the above technical problems, and as a result, a novel synthetic intermediate capable of mass-producing compound (I) and (II) can produce compound (III) and (IV). The present invention has been found to be useful, and the present invention has been completed by finding compounds (I) and (II) and their preparation methods.

그러므로, 본 발명의 목적은 고수율, 고순도 및 낮은 가격으로 제조한 하기 화합물(V)의 화합물로부터 화합물(I)과 (II)의 혼합물을 제조하는 방법 및 이들의 혼합물로부터 신규 합성 중간체인 화합물(I),(II) 및 그들의 제조방법을 제공하는 것이다.Therefore, an object of the present invention is to provide a process for preparing a mixture of compounds (I) and (II) from compounds of the following compound (V) prepared in high yield, high purity and low price and a compound which is a novel synthetic intermediate from the mixture thereof ( I), (II) and their manufacturing method.

이하 본 발명을 구체적으로 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail.

촉매존재하에서, 디엘-무스콘(V)과 케탈화제와의 케탈화반응으로 디메칠 디엘-무스콘 케탈(VI)을 제조한 다음, 화합물(VI)을 1,4-디-O-알킬 또는 아릴-2,3-L-스레이톨(VII)과의 케탈교환반응으로 화합물(I)과 (II)의 혼합물을 제조하여 이 혼합물로부터 재결정법, 크로마토 그래피법등의 방법을 이용하여 각각의 화합물(I)과 (II)를 제조한다.In the presence of a catalyst, dimethyl-diesel-muscon ketal (VI) was prepared by ketalization of die-muscon (V) with a ketalizing agent, and then compound (VI) was prepared using 1,4-di-O-alkyl or A mixture of compounds (I) and (II) was prepared by ketal exchange with aryl-2,3-L- stolitol (VII), and from each mixture was prepared by recrystallization, chromatography, or the like. Prepare I) and (II).

본 발명을 좀더 상세히 설명하면 다음과 같다.The present invention will be described in more detail as follows.

케탈화반응은 촉매로써 몬트몰리노나이트 K-10과 케탈화제인 CH(OR)3(R=Me,Et)를 유기용매 속에서 1시간동안 교반하여 준 후 미리 유기용매에 녹인 디엘-무스콘(V)을 첨가하고 40분-90분동안 교반한 다음, 감압여과하여 얻은 몰트몰리노나이트 K-10의 잔사를 유기용매로 충분히 세척한 후 상기 유기용매와 합하고 감압유거하여 화합물(VI)을 제조한다.The ketalization reaction was carried out by stirring Montmololinite K-10 as a catalyst and CH (OR) 3 (R = Me, Et) as a catalyst in an organic solvent for 1 hour, and then DL-Muscon dissolved in an organic solvent in advance. After (V) was added and stirred for 40 minutes to 90 minutes, the residue of maltmolinoite K-10 obtained by filtration under reduced pressure was sufficiently washed with an organic solvent, combined with the organic solvent, and distilled under reduced pressure to obtain Compound (VI). Manufacture.

이때, 촉매로써는 건조된 HCl, TsOH, NH3Cl, PhSO2NHOH, NaOH, La(또는 Ce, Nd, Er, Yb)Cl3, 산성 이온교환수지, 몬트몰리노나이트 K-10 등을 사용할 수 있으며, 그중에서 몬트몰리노나이트 K-10가 바람직하다.In this case, as the catalyst, dried HCl, TsOH, NH 3 Cl, PhSO 2 NHOH, NaOH, La (or Ce, Nd, Er, Yb) Cl 3 , an acidic ion exchange resin, montmolinonit K-10 and the like can be used. Among them, montmolinoite K-10 is preferable.

몬트몰리노나이트 K-10의 사용량은 화합물(V)에 대하여 중량비로 1∼4배를 사용할 수 있으며, 그중에서 2∼3배를 사용하는 것이 가장 바람직하다.The use amount of montmolinonit K-10 can be used 1 to 4 times by weight relative to compound (V), and it is most preferable to use 2 to 3 times.

한편, 케탈화제로는 MeOH, MeOH/(MeO)4Si, Me2SO4/MeOH CH(OEt)3, CH(OMe)3등이 사용되는데, 그중에서 CH(OEt)3또는 CH(OMe)3를 사용하는 것이 가장 바람직하다.Meanwhile, as the ketalizing agent, MeOH, MeOH / (MeO) 4 Si, Me 2 SO 4 / MeOH CH (OEt) 3 , CH (OMe) 3, and the like are used, among which CH (OEt) 3 or CH (OMe) Most preferably, 3 is used.

CH(OMe)3의 사용량은 화합물(V)에 대하여 몰비율로 2-10배를 사용하여 반응시킬 수 있으며, 그중에서 4∼8배를 사용하는 것이 가장 바람직하다.The amount of CH (OMe) 3 can be reacted with 2-10 times in molar ratio with respect to compound (V), of which 4-8 times are most preferred.

또한, 유기용매로는 극성용매인 메탄올, 에탄올, 프로필알콜등이 사용되고, 무극성용매로는 노르말-헥산, 사염화탄소등이 사용되며, 그 중에서 노르말-헥산을 사용하는 것이 가장 바람직하다.In addition, as the organic solvent, methanol, ethanol, propyl alcohol, and the like, which are polar solvents, are used. As the nonpolar solvent, normal-hexane and carbon tetrachloride are used, and among them, normal-hexane is most preferable.

반응온도는 환류온도 또는 실온에서 행할 수 있으며, 특히 실온에서 실시하는 것이 가장 바람직하다.The reaction temperature can be carried out at reflux or at room temperature, and most preferably at room temperature.

케탈교환반응은 신촉매하에서, 화합물(VI)을 무수벤젠에 용해시킨 다음 화합물(VII) 을 가하고 가열하여 용해시킨 다음 1∼2시간동안 가열하거나, 또는 화합물(VI)을 유기용매에 용해시킨 다음 화합물(VII)을 가하여 실온에서 1∼2시간동안 교반하여 화합물(I)과 (II)의 혼합물을 제조한다.The ketal exchange reaction is carried out by dissolving compound (VI) in anhydrous benzene, adding compound (VII), heating and dissolving for 1 to 2 hours, or dissolving compound (VI) in an organic solvent under a new catalyst. Compound (VII) was added and stirred at room temperature for 1-2 hours to prepare a mixture of compounds (I) and (II).

한편, 촉매를 사용하지 않는 경우에는 벤젠이나 극성 유기용매에 화합물(VI), (VII)을 용해시켜 환류시키거나 또는 실온에서 8∼24시간동안 교반한다.On the other hand, when no catalyst is used, the compounds (VI) and (VII) are dissolved and refluxed in benzene or a polar organic solvent or stirred at room temperature for 8 to 24 hours.

산촉매로는 트리후로로보란 이서레이트, 파라톨루엔설폰산, 파라톨루엔설폰산 피리딘 염 등을 사용할 수 있으며, 그 중에서 트리후로로보란 이서레이트 또는 파라톨루엔설폰산을 사용하는 것이 가장 바람직하고, 그 사용량은 화합물(V)에 대하여 0.1∼0.005 몰비율로 사용할 수 있으며, 0.01∼0.03몰비율로 사용하는 것이 가장 바람직하다.Examples of the acid catalyst may include trifluororoboran sulphate, paratoluenesulfonic acid, paratoluenesulfonic acid pyridine salt, and the like. Among them, trifluororoboran sulphate or paratoluenesulfonic acid is most preferably used. It can be used in 0.1-0.005 molar ratio with respect to silver compound (V), and it is most preferable to use in 0.01-0.03 molar ratio.

이때, 사용되는 유기용매로는 클로로포름, 디클로로메탄, 에테르, 에탄올, 메탄올 등을 사용할 수 있으며, 이중에서 디클로로메탄 또는 에테르를 사용하는 것이 가장 바람직하다.In this case, chloroform, dichloromethane, ether, ethanol, methanol, and the like may be used as the organic solvent, and among them, dichloromethane or ether is most preferable.

한편 화합물(I)과 (II)의 혼합물중에서 각각을 분리하는 방법은 R1그룹이 토실기일 경우에는, 상기에서 제조한 화합물(I)과 (II)의 혼합물을 극성용매인 메탄올, 메탄올-클로로포름, 헥산-클로로포름, 석유에테르-클로로포름등의 혼합액 혹은, 석유에테르, 헥산등의 무극성유기용매를 사용하여 재결정 방법에 의하여 화합물(I)과 (II)를 각각 얻을 수 있으며, 이중에서 극성용매인 메탄올을 사용하는 경우가 가장 바람직하다.On the other hand, in the method of separating each of the mixtures of the compounds (I) and (II), when the R 1 group is a tosyl group, the mixture of the compounds (I) and (II) prepared above is a polar solvent of methanol, methanol-chloroform Compounds (I) and (II) can be obtained by recrystallization using a mixture of hexane-chloroform, petroleum ether-chloroform, or a nonpolar organic solvent such as petroleum ether or hexane. Most preferably, is used.

또한, R1그룹이 메칠, 메실, 토실 또는, 벤질기인 경우에는, 상기에서 제조한 화합물(I)과 (II)의 혼합물을 아세토니트릴-물 혼합액, 클로로포름-헥산 혼합액, 헥산-에틸아세테이트 혼합액을 사용하여 크로마토그래피법(MPLC)을 행하여 화합물(I)와 (II)의 화합물을 각각 얻을 수 있으며, 이중에서 아세토니트릴-물 혼합액을 사용하는 것이 가장 바람직하다.In the case where the R 1 group is methyl, mesyl, tosyl or benzyl group, the mixture of the compound (I) and (II) prepared above may be added to an acetonitrile-water mixture, a chloroform-hexane mixture, and a hexane-ethyl acetate mixture. Chromatography (MPLC) can be used to obtain compounds of Compounds (I) and (II), respectively, of which acetonitrile-water mixture is most preferred.

이때, 칼럼의 규격은 41.4mm*250mm을 사용하였으며 유속(ml/분)은 50, 검출기는 자외선 254nm를 사용하였으며, 충진제는 C8, C18을 사용할 수 있으며, 그 중에서 C18을 사용하는 것이 가장 바람직하다.At this time, the column size was 41.4mm * 250mm, the flow rate (ml / min) was 50, the detector was ultraviolet 254nm, and the filler was C 8 , C 18 can be used, among which C 18 is used. Most preferred.

다음의 실시예를 들어 본 발명을 상세히 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail with reference to the following examples.

실시예에 의하여 본 발명의 특허청구의 범위가 한정되는 것은 아니다.The scope of the claims of the present invention is not limited by the examples.

[실시예 1]Example 1

엘-3-메칠-시클로펜타데칸-1-온 1,4-디-O-토실-2,3-L-스레이톨 케탈[(I),R1=Tosyl]과 디-3-메칠-시클로펜타데칸-1-온 1,4-디-O-토실-2,3-L-스레이톨 케탈[(II),R1=Tosyl]의 제조L-3-Methyl-cyclopentadecan-1-one 1,4-di-O-tosyl-2,3-L-stolitol ketal [(I), R 1 = Tosyl] and di-3-methyl-cyclo Preparation of pentadecane-1-one 1,4-di-O-tosyl-2,3-L- stolitol ketal [(II), R 1 = Tosyl]

질소로 충진된 100ml 1구 플라스크에 몬트몰리노나이트 K-10 25g과 CH(OMe)338ml를 넣고 1시간동안 실온에서 교반한다. 미리 무수헥산 30ml에 용해시킨 디엘-무스콘(V) 10.0g을 반응기에 가하고 1.5시간동안 실온에서 교반한 다음 감압여과하여 얻은 몬트몰리노나이트 K-10 잔사를 무수헥산 300ml로 세척하고, 상기 유기용매와 합하여 감압유거하여 얻은 디메칠 디엘-무스콘 케탈(VI)에 1,4-디-O-토실-2,3-L-스레이톨(VII, R=tosyl) 18.07g, 디클로로메탄 25ml를 순차적으로 가하고 트리후루오로보란 이서레이트 0.25ml를 가한 다음 실온에서 2시간동안 교반한다.Into a 100 ml one-necked flask filled with nitrogen, 25 g of montmolinoite K-10 and 38 ml of CH (OMe) 3 were added and stirred at room temperature for 1 hour. 10.0 g of DL-muscon (V), dissolved in 30 ml of anhydrous hexane in advance, was added to the reactor, stirred at room temperature for 1.5 hours, and the montmolinolite K-10 residue obtained by filtration under reduced pressure was washed with 300 ml of anhydrous hexane, and the organic 18.07 g of 1,4-di-O-tosyl-2,3-L-stolitol (VII, R = tosyl) and 25 ml of dichloromethane were added to dimethyl DL-muscon ketal (VI) obtained by distillation under reduced pressure in combination with a solvent. The solution was added sequentially, 0.25 ml of trifluorouroborane acrylate was added, followed by stirring at room temperature for 2 hours.

반응액을 디클로로메탄 200ml로 희석시키고 물 100ml, 포화 소금물로 순으로 세척한 다음 황산마그네슘으로 건조하고, 감압유거하여 얻은 미황색 고체 27.12g을 헥산 60ml로 충분히 세척하여 하기 구조식을 갖는 화합물[(I),R1=Tosyl]과 [(II),R1=Tosyl]의 혼합물 25.25g을 얻었다.The reaction solution was diluted with 200 ml of dichloromethane, washed sequentially with 100 ml of water and saturated brine, dried over magnesium sulfate, and 27.12 g of a slightly yellow solid obtained by distillation under reduced pressure was sufficiently washed with 60 ml of hexane to give a compound having the following structural formula [(I) , 25.25 g of a mixture of R 1 = Tosyl] and [(II), R 1 = Tosyl].

이 혼합물을 메탄올을 사용하여 3회에 걸쳐 재결정하여 미황색고체인 화합물[(I),R1=Tosyl]을 9.35g(37%)얻었다.(순도 99%)The mixture was recrystallized three times with methanol to obtain 9.35 g (37%) of a pale yellow solid [(I), R 1 = Tosyl] (purity 99%).

mp ; 91.5-92.5℃mp; 91.5-92.5 ℃

1H NMR(CDCl3, ppm) ; 1 H NMR (CDCl 3 , ppm);

7.77(4Htosyl, d, 8.8Hz), 7.36(4Htosyl, d, 8.8Hz), 4.07(4H2'2, m), 3.97(2H1'1, m),7.77 (4H tosyl , d, 8.8 Hz), 7.36 (4H tosyl , d, 8.8 Hz), 4.07 (4H 2'2 , m), 3.97 (2H 1'1 , m),

2.46(6Htosyl, s), 1.65-1.14(27Hring, hump), 0.82(3H16, d, 7.0Hz)2.46 (6H tosyl , s), 1.65-1.14 (27H ring , hump), 0.82 (3H 16 , d, 7.0 Hz)

13C NMR(CDCl3, ppm) ; 13 C NMR (CDCl 3 , ppm);

Ctosyl: 145.02, 144.99, 132.43, 132.41, 129.84, 129.82, 127.77C tosyl : 145.02, 144.99, 132.43, 132.41, 129.84, 129.82, 127.77

114.52(C1), 75.00(C1'), 74.45(C1), 68.46(C2'), 68.34(C2), 44.22((C2),114.52 (C 1 ), 75.00 (C 1 ' ), 74.45 (C 1 ), 68.46 (C 2' ), 68.34 (C 2 ), 44.22 ((C 2 ),

36.59(C15), 35.97(C4), 27.64(C3), 20.86(C16)36.59 (C 15 ), 35.97 (C 4 ), 27.64 (C 3 ), 20.86 (C 16 )

Cring: 27.03, 26.96, 26.57, 26.43, 26.29, 26.09, 25.89, 24.86, 21.78, 21.46,C ring : 27.03, 26.96, 26.57, 26.43, 26.29, 26.09, 25.89, 24.86, 21.78, 21.46,

Mass (m/e) : 650.3(M+), 607.3, 531.1, 481.0, 467.1, 390.0, 369.2, 327.0, 154.8, 90.8, 68.8Mass (m / e): 650.3 (M + ), 607.3, 531.1, 481.0, 467.1, 390.0, 369.2, 327.0, 154.8, 90.8, 68.8

IR (KBr, cm-1) : 2927, 2855, 1361, 1180, 1097, 971, 945, 854, 814IR (KBr, cm -1 ): 2927, 2855, 1361, 1180, 1097, 971, 945, 854, 814

[α]27 D= -1.48(c 1.0, CHCl3, 100mm)[α] 27 D = -1.48 (c 1.0, CHCl 3 , 100 mm)

상기 화합물[(I),R1=Tosyl]을 제조하고 남은 모액으로부터 얻은 화합물을 메탄올을 사용하여 3회 재결정을 실시하여 미황색의 고체인 화합물[(II),R1=Tosyl] 7.74g(31%)을 얻었다.Wherein the compound [(I), R 1 = Tosyl] prepared, and to the compound obtained from the remaining mother liquor using methanol as a pale yellow solid was recrystallized three times to carry out the compound [(II), R 1 = Tosyl] 7.74g (31 %) Was obtained.

(순도 99%)(99% purity)

mp ; 84.0-85.0℃mp; 84.0-85.0 ℃

1H NMR(CDCl3, ppm) ; 1 H NMR (CDCl 3 , ppm);

7.78(4Htosyl, d, 8.8Hz), 7.35(4Htosyl, d, 8.8Hz), 4.10(4H2'2, m), 3.92(2H1'1, m),7.78 (4H tosyl , d, 8.8 Hz), 7.35 (4H tosyl , d, 8.8 Hz), 4.10 (4H 2'2 , m), 3.92 (2H 1'1 , m),

2.46(6Htosyl, s), 1.60-1.06(27Hring, hump), 0.82(3H16, d, 7.0Hz)2.46 (6H tosyl , s), 1.60-1.06 (27H ring , hump), 0.82 (3H 16 , d, 7.0 Hz)

13C NMR(CDCl3, ppm) ; 13 C NMR (CDCl 3 , ppm);

Ctosyl: 144.98, 144.96, 132.53, 132.50, 129.79, 127.83,C tosyl : 144.98, 144.96, 132.53, 132.50, 129.79, 127.83,

114.37(C1), 74.72(C1'), 74.40(C1), 68.48(C2'), 68.39(C2), 43.84(C2),114.37 (C 1 ), 74.72 (C 1 ′ ), 74.40 (C 1 ), 68.48 (C 2 ′ ), 68.39 (C 2 ), 43.84 (C 2 ),

36.67(C15), 36.10(C4), 27.69(C3), 20.67(C16)36.67 (C 15 ), 36.10 (C 4 ), 27.69 (C 3 ), 20.67 (C 16 )

Cring: 27.01, 26.95, 26.61, 26.46, 26.43, 26.18, 25.94, 25.91, 24.82, 21.98, 21.46C ring : 27.01, 26.95, 26.61, 26.46, 26.43, 26.18, 25.94, 25.91, 24.82, 21.98, 21.46

Mass (m/e) : 650.3(M+), 607.3, 531.1, 481.0, 467.1, 390.0, 369.2, 327.0, 154.8, 90.8, 68.8Mass (m / e): 650.3 (M + ), 607.3, 531.1, 481.0, 467.1, 390.0, 369.2, 327.0, 154.8, 90.8, 68.8

IR (KBr, cm-1) : 2926, 2856, 1353, 1176, 1099, 978, 939, 858, 815IR (KBr, cm -1 ): 2926, 2856, 1353, 1176, 1099, 978, 939, 858, 815

[α]27 D= -15.67(c 1.0, CHCl3, 100mm)[α] 27 D = -15.67 (c 1.0, CHCl 3 , 100 mm)

[실시예 2]Example 2

엘-3-메칠-시클로펜타데칸-1-온 1,4-디-O-토실-2,3-L-스레이톨 케탈[(I),R1=Tosyl]과 디-3-메칠-시클로펜타데칸-1-온 1,4-디-O-토실-2,3-L-스레이톨 케탈[(II),R1=Tosyl]의 제조L-3-Methyl-cyclopentadecan-1-one 1,4-di-O-tosyl-2,3-L-stolitol ketal [(I), R 1 = Tosyl] and di-3-methyl-cyclo Preparation of pentadecane-1-one 1,4-di-O-tosyl-2,3-L- stolitol ketal [(II), R 1 = Tosyl]

상기 실시예 1에서와 디메칠 디엘-무스콘 케탈(VI)을 제조한 반응액에 화합물(VII, R=Tosyl)18.07g과 벤젠 350ml와 파라톨루엔설폰산 또는 파라톨루엔설폰산 피리딘염 1mg을 가하고 가열하여 환류시킨다.18.07 g of Compound (VII, R = Tosyl), 350 ml of benzene, 1 mg of paratoluenesulfonic acid or paratoluenesulfonic acid pyridine salt were added to the reaction solution of Dimethyl DL-Muscon Ketal (VI). Heated to reflux.

0.5∼1시간 후 반응액을 상온으로 냉각시키고 200ml의 에테로 또는 디클로로메탄으로 희석시킨 다음, 이하 실시예 1과 같은 조작을 실시하여 백색의 고체인 상기 표제화합물(I)과 (II)의 혼합물을 25.25g 얻었다.After 0.5 to 1 hour, the reaction solution was cooled to room temperature, diluted with 200 ml of ether or dichloromethane, and then the same procedure as in Example 1 was carried out to obtain a mixture of the title compound (I) and (II) as a white solid. Obtained 25.25 g.

이하의 재결정 조작은 실시예 1과 같은 방법으로 실시한다.The following recrystallization operation is performed by the method similar to Example 1.

[실시예 3]Example 3

엘-3-메칠-시클로펜타데칸-1-온 1,4-디-O-토실-2,3-L-스레이톨 케탈[(I),R1=Tosyl]과 디-3-메칠-시클로펜타데칸-1-온 1,4-디-O-토실-2,3-L-스레이톨 케탈[(II),R1=Tosyl]의 제조L-3-Methyl-cyclopentadecan-1-one 1,4-di-O-tosyl-2,3-L-stolitol ketal [(I), R 1 = Tosyl] and di-3-methyl-cyclo Preparation of pentadecane-1-one 1,4-di-O-tosyl-2,3-L- stolitol ketal [(II), R 1 = Tosyl]

상기 실시예 1과 같이 디메칠 디엘-무스콘 케탈(VI)을 제조하고 여기에 1,4-디-O-토실-2,3-L-스레이톨(VII, R=tosyl)18.07g과 벤젠 600ml를 가한 다음 상온에서 1일간 교반하였다.Dimethyl DL-muscon ketal (VI) was prepared as in Example 1, and 1,4-di-O-tosyl-2,3-L- stolitol (VII, R = tosyl) 18.07 g and benzene were prepared. 600 ml was added and then stirred at room temperature for 1 day.

이 반응액을 200ml의 에테르 또는 디클로로메탄으로 희석시키고 이하의 조작을 실시예 1과 같은 동일한 방법으로 실시하여 상기 표제화합물(I)과 (II)의 혼합물을 25.25g 얻었다.The reaction solution was diluted with 200 ml of ether or dichloromethane and the following procedure was carried out in the same manner as in Example 1 to obtain 25.25 g of a mixture of the titled compounds (I) and (II).

이하의 재결정 조작은 실시예 1과 같은 방법으로 실시한다.The following recrystallization operation is performed by the method similar to Example 1.

[실시예 4]Example 4

엘-3-메칠-시클로펜타데칸-1-온 1,4-디-O-토실-2,3-L-스레이톨 케탈[(I),R1=Tosyl]과 디-3-메칠-시클로펜타데칸-1-온 1,4-디-O-토실-2,3-L-스레이톨 케탈[(II),R1=Tosyl]의 제조L-3-Methyl-cyclopentadecan-1-one 1,4-di-O-tosyl-2,3-L-stolitol ketal [(I), R 1 = Tosyl] and di-3-methyl-cyclo Preparation of pentadecane-1-one 1,4-di-O-tosyl-2,3-L- stolitol ketal [(II), R 1 = Tosyl]

250ml 3구 동근플라스크에 디엘-무스콘(V) 2.0g, 화합물(VII, R=tosyl) 3.6g, 파라톨루엔 설폰산 0.16g, 무수벤젠 100ml를 가하여 용해시킨 다음 7일동안 생성되는 물을 제거하면서, 가열·교반한 후 반응액을 상온으로 냉각하고 200ml의 에테르로 희석시키고 포화 중탄산나트륨과 소금물 순으로 세척한 다음 황산마그네슘으로 건조시키고, 감압여과하여 얻은 유기용매를 감압유거하여 상기 표제화합물(I)과 (II)의 혼합물을 5.5g 얻었다.2.0 g of DL-muscon (V), 3.6 g of compound (VII, R = tosyl), 0.16 g of paratoluene sulfonic acid, and 100 ml of anhydrous benzene were dissolved in a 250 ml three-necked copper flask to remove water produced for 7 days. After heating and stirring, the reaction mixture was cooled to room temperature, diluted with 200 ml of ether, washed with saturated sodium bicarbonate and brine, dried over magnesium sulfate, and the organic solvent obtained by filtration under reduced pressure was distilled under reduced pressure to obtain the title compound ( 5.5 g of a mixture of I) and (II) was obtained.

이하의 재결정 조작은 실시예 1과 같은 방법으로 실시한다.The following recrystallization operation is performed by the method similar to Example 1.

[실시예 5]Example 5

엘-3-메칠-시클로펜타데칸-1-온 1,4-디-O-벤질-2,3-L-스레이톨 케탈[(I),R1=Benzyl]과 디-3-메칠-시클로펜타데칸-1-온 1,4-디-O-벤질-2,3-L-스레이톨 케탈[(II),R1=Benzyl]의 제조L-3-Methyl-cyclopentadecan-1-one 1,4-di-O-benzyl-2,3-L-stolitol ketal [(I), R 1 = Benzyl] and di-3-methyl-cyclo Preparation of pentadecane-1-one 1,4-di-O-benzyl-2,3-L- stolitol ketal [(II), R 1 = Benzyl]

질소로 충진된 50ml 1구 플라스크에 몬트몰리노나이트 K-10 12.5g과 CH(OMe)318ml를 가하고 1시간동안 실온에서 교반한다. 미리 무수헥산 15ml에 용해시킨 디엘-무스콘(V) 5.0g을 반응기에 가하고 1.5시간동안 실온에서 교반하여 준 다음, 감압여과하여 얻은 잔사인 몬트몰리노나이트 K-10을 무수헥산 150ml로 세척하고, 상기 유기용매와 합한 다음 감압유거하여 얻은 디메칠 디엘-무스콘 케탈(VI)에 화합물(VII, R=Benzyl) 4.9g과 디클로로메탄 13ml, 트리후루오로보란 이서레이트 0.03ml를 가한 후 실온에서 2시간동안 교반한다.To a 50 ml one-necked flask filled with nitrogen, 12.5 g of montmolinonite K-10 and 18 ml of CH (OMe) 3 were added and stirred at room temperature for 1 hour. 5.0 g of DL-muscon (V), dissolved in 15 ml of anhydrous hexane in advance, was added to the reactor and stirred at room temperature for 1.5 hours. Then, the residue obtained by filtration under reduced pressure was washed with 150 ml of anhydrous hexane. , 4.9 g of a compound (VII, R = Benzyl), 13 ml of dichloromethane, and 0.03 ml of trifururoborane acrylate were added to dimethyl DL-muscon ketal (VI) obtained by combining with the organic solvent and distilling under reduced pressure. Stir for 2 hours.

디클로로메탄 100ml로 희석시킨 후 물 50ml와 포화 소금물 순으로 세척하여 준 다음 황산마그네슘으로 건조시키고, 여과하여 얻은 유기용매를 감압유거하여 미황색의 기름상 물질인 하기 구조식을 갖는 화학물[(I),R1=Benzyl]과 [(II),R1=Benzyl]의 혼합물 8.5g을 얻었다. 이 혼합물을 MPLC를 3회 실시하여 상기 표제화합물(I)과 (II)화합물을 각각 4.09g(48%)을 얻었다.Dilute with 100 ml of dichloromethane, wash with 50 ml of water and saturated brine, and then dry with magnesium sulfate, filter the organic solvent obtained by distilling under reduced pressure, and then have a yellowish oily substance having the following structural formula [(I), 8.5 g of a mixture of R 1 = Benzyl] and [(II), R 1 = Benzyl] was obtained. The mixture was subjected to MPLC three times to obtain 4.09 g (48%) of the title compound (I) and (II), respectively.

이때, 41.4mm*250mm의 컬럼(C18)을 사용하여 아세토니트릴-물 혼합액 85% 전개액으로, 유속은 50ml/분으로, 검출기는 자외선 254nm를 사용하였다.At this time, the acetonitrile-water mixture 85% developing solution using a 41.4mm * 250mm column ( C18 ), the flow rate is 50ml / min, the detector was ultraviolet 254nm.

1H NMR(CDCl3, ppm) ; 1 H NMR (CDCl 3 , ppm);

7.31(10Hph, m), 4.58(2H3', s), 4.57(2H3, s), 4.0(2H1,1', m), 3.59(4H2,2', m),7.31 (10H ph , m), 4.58 (2H 3 ' , s), 4.57 (2H 3 , s), 4.0 (2H 1,1' , m), 3.59 (4H 2,2 ' , m),

1.81-1.09(27Hring, hump), 0.93(3H, d, 7.04Hz)1.81-1.09 (27H ring , hump), 0.93 (3H, d, 7.04 Hz)

13C-NMR(CDCl3, ppm) ; 13 C-NMR (CDCl 3 , ppm);

Cph; 139.16, 128.30, 127.52,C ph ; 139.16, 128.30, 127.52,

113.51(C1), 77.88((C1'), 77.31(C1), 73.41(C3',3), 71.06(C2'), 70.80(C2),113.51 (C 1 ), 77.88 ((C 1 ′ ), 77.31 (C 1 ), 73.41 (C 3 ′, 3 ), 71.06 (C 2 ′ ), 70.80 (C 2 ),

44.80(C2), 37.06(C15), 27.96(C4), 27.35(C3), 21.36(C16),44.80 (C 2 ), 37.06 (C 15 ), 27.96 (C 4 ), 27.35 (C 3 ), 21.36 (C 16 ),

Cring: 27.20, 26.80, 26.66, 26.62, 26.53, 26.31, 26.10, 25.12, 22.12,C ring : 27.20, 26.80, 26.66, 26.62, 26.53, 26.31, 26.10, 25.12, 22.12,

IR (neat, cm-1) : 3088, 3064, 3031, 2927, 2857, 1947, 1872, 1806, 1736, 1497, 1455, 1029, 735, 698IR (neat, cm -1 ): 3088, 3064, 3031, 2927, 2857, 1947, 1872, 1806, 1736, 1497, 1455, 1029, 735, 698

[α]27 D= 7.55(c 1.0, 헥산, 100mm)[α] 27 D = 7.55 (c 1.0, Hexane, 100 mm)

1H NMR(CDCl3, ppm) ; 1 H NMR (CDCl 3 , ppm);

7.31(10Hph, m), 4.57(4H3', 3, s), 3.98(2H1,1', m), 3.60(4H2,2', m),7.31 (10H ph , m), 4.57 (4H 3 ', 3 , s), 3.98 (2H 1,1' , m), 3.60 (4H 2,2 ' , m),

1.78-1.10(27Hring, hump), 0.95(3H, d, 7.04Hz)1.78-1.10 (27H ring , hump), 0.95 (3H, d, 7.04 Hz)

13C-NMR(CDCl3, ppm) ; 13 C-NMR (CDCl 3 , ppm);

Cph; 138.20, 138.15, 128.28, 127.55, 127.51,C ph ; 138.20, 138.15, 128.28, 127.55, 127.51,

113.39(C1), 77.36(C1'), 77.30(C1), 73.45(C3'), 73.37(C,3), 70.89(C2'), 70.65(C2), 44.36(C2), 37.21(C15), 36.45(C4), 28.01(C3), 21.18(C16),113.39 (C 1 ), 77.36 (C 1 ' ), 77.30 (C 1 ), 73.45 (C 3' ), 73.37 (C , 3 ), 70.89 (C 2 ' ), 70.65 (C 2 ), 44.36 (C 2 ), 37.21 (C 15 ), 36.45 (C 4 ), 28.01 (C 3 ), 21.18 (C 16 ),

Cring: 27.31, 27.17, 26.60, 26.64, 26.61, 26.40, 26.14, 26.11, 25.05, 22.28C ring : 27.31, 27.17, 26.60, 26.64, 26.61, 26.40, 26.14, 26.11, 25.05, 22.28

IR (neat, cm-1) : 3088, 3064, 3030, 2927, 2858, 1947, 1872, 1807, 1740, 1497, 1455, 1029, 735, 698IR (neat, cm -1 ): 3088, 3064, 3030, 2927, 2858, 1947, 1872, 1807, 1740, 1497, 1455, 1029, 735, 698

[α]27 D= -3.53(c 1.0, 헥산, 100mm)[a] 27 D = -3.53 (c 1.0, hexane, 100 mm)

Claims (11)

하기 구조식을 갖는 화합물 (I) 또는 (II).Compound (I) or (II) having the following structural formula. 출발물질인 화합물(V)를 실온 또는 환류온도에서 촉매하 유기용매와 케탈화제를 사용하여 화합물(VI)을 제조하고, 화합물(VI)을 화합물(VII)과 케탈교환반응시켜 화합물(I)과 (II)의 혼합물을 제조한 다음 유기용매로 재결정화 또는 크로마토크래피를 행하여 화합물(I) 또는 (II)를 분리, 제조함을 특징으로 하는 방법.Compound (V) was prepared by using a organic solvent and a ketalizing agent under a catalyst at room temperature or reflux at room temperature or reflux temperature. Compound (VI) was subjected to ketal exchange with compound (VII) to react with compound (I). A method of preparing a mixture of (II) and then recrystallization or chromatography with an organic solvent to separate and prepare compound (I) or (II). 제2항에 있어서, 촉매로는 건조된 HCl, TsOH, NH4Cl, PhSO2NHOH, NaOH, La(또는, Ce, Nd, Er, Yb)Cl3, 산성이온교환수지, 몬트몰리노나이트 K-10등을 사용할 수 있으며, 그 중에서 몬트몰리노나이트 K-10를 사용함을 특징으로 하는 방법.The catalyst of claim 2, wherein the catalyst is dried HCl, TsOH, NH 4 Cl, PhSO 2 NHOH, NaOH, La (or Ce, Nd, Er, Yb) Cl 3 , acidic ion exchange resin, montmolinoite K -10, etc. can be used, and among them, the method characterized in that the use of montmolinoite K-10. 제3항에 있어서, 촉매의 사용량은 화합물(V)의 화합물에 대하여 중량비로 1-4배량을 사용할 수 있으며, 그중에서 2∼3배량을 사용함을 특징으로 하는 방법.The method according to claim 3, wherein the amount of the catalyst is 1 to 4 times the weight ratio of the compound of the compound (V), wherein 2 to 3 times the amount is used. 제2항에 있어서, 케탈화제로는 MeOH, MeOH/(MeO)4Si, Me2SO4/MeOH, CH(OEt)3, CH(OMe)3등을 사용할 수 있으며, 그중에서 CH(OEt)3또는, CH(OMe)3을 사용함을 특징으로 하는 방법.The method of claim 2, wherein the ketalizing agent may be used MeOH, MeOH / (MeO) 4 Si, Me 2 SO 4 / MeOH, CH (OEt) 3 , CH (OMe) 3, etc., wherein CH (OEt) 3 or, CH (OMe) 3 . 제5항에 있어서, 케탈화제의 사용량은 화합물(V)의 화합물에 대하여 몰비율로 2∼10배몰을 사용할 수 있으며, 그 중에서 4∼8배 몰을 사용함을 특징으로 하는 방법.The method according to claim 5, wherein the ketalizing agent is used in a molar ratio of 2 to 10 times the molar ratio with respect to the compound of the compound (V), wherein 4 to 8 times the mole is used. 제2항에 있어서, 유기용매는 극성용매인 메탄올, 에탄올, 프로필알콜등이 사용되며, 무극성용매로는 노르말-헥산, 사염화탄소등이 사용되며, 그중에서 노르말-헥산을 사용함을 특징으로 하는 방법.The method of claim 2, wherein the organic solvent is a polar solvent such as methanol, ethanol, propyl alcohol, and the like, and the non-polar solvent is a normal-hexane, carbon tetrachloride, etc., characterized in that the normal-hexane is used. 제2항에 있어서, 케탈교환반응은 산촉매하에서, 화합물(VI)을 무수벤젠에 용해시킨 다음 화합물(VII)을 가하고 가열, 용해시킨 다음 1-2시간 가열하거나, 또는 화합물(VI)을 유기 용매에 용해시킨 다음 화합물(VII)을 가하여 실온에서 1-2시간 교반하여 완료됨을 특징으로 하는 방법.The method of claim 2, wherein the ketal exchange reaction is carried out by dissolving compound (VI) in anhydrous benzene under an acid catalyst and then adding compound (VII), heating and dissolving and heating for 1-2 hours, or compound (VI) in an organic solvent. Dissolved in and then added to compound (VII) to completion for 1-2 hours at room temperature. 제2항에 있어서, 케탈교환반응이 촉매없이 벤젠이나 극성유기용매에 화합물(VI)과 (VII)을 용해시키고 실온 또는 가열교반하여 완료됨을 특징으로하는 방법.The method according to claim 2, wherein the ketal exchange reaction is completed by dissolving the compounds (VI) and (VII) in benzene or a polar organic solvent without a catalyst and stirring at room temperature or by heating. 제8항에 있어서, 산촉매로는 트리후루오보란 이서레이트, 파라톨루엔설폰산, 파라톨루엔설폰산 피리딘염을 사용하며, 그중에서 트리후루오보란 이서레이트 또는 파라톨루엔설폰산을 사용함을 특징으로 하는 방법.9. The acid catalyst according to claim 8, wherein trifuruoborane isomerate, paratoluenesulfonic acid, paratoluenesulfonic acid pyridine salt is used, wherein trifuroborane isomerate or paratoluenesulfonic acid is used. Way. 제2항에 있어서, 화합물(I)과 (II)를 분리시 유기용매는 극성 또는 무극성용매중 단독 혹은 2종이상의 혼합용매를 사용하며, 그중에서 특히 메탄올 또는 아세토니트릴-물 혼합액을 사용함을 특징으로 하는 방법.The organic solvent according to claim 2, wherein the organic solvent is separated from the polar solvent or the nonpolar solvent using two or more mixed solvents, in particular, methanol or acetonitrile-water mixture. How to.
KR1019970000043A 1997-01-04 1997-01-04 Novel synthetic intermediate of muscone and the preparation thereof KR100226621B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019970000043A KR100226621B1 (en) 1997-01-04 1997-01-04 Novel synthetic intermediate of muscone and the preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019970000043A KR100226621B1 (en) 1997-01-04 1997-01-04 Novel synthetic intermediate of muscone and the preparation thereof

Publications (2)

Publication Number Publication Date
KR19980065188A true KR19980065188A (en) 1998-10-15
KR100226621B1 KR100226621B1 (en) 1999-10-15

Family

ID=19494070

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970000043A KR100226621B1 (en) 1997-01-04 1997-01-04 Novel synthetic intermediate of muscone and the preparation thereof

Country Status (1)

Country Link
KR (1) KR100226621B1 (en)

Also Published As

Publication number Publication date
KR100226621B1 (en) 1999-10-15

Similar Documents

Publication Publication Date Title
KR102068381B1 (en) Process for preparing bile acid derivatives
JP2019524770A (en) Process for producing spiroketal substituted cyclic ketoenols
RU2388753C2 (en) Method of obtaining intermediate product taking part in irbesartan synthesis
JPH0261476B2 (en)
AU2021314375A1 (en) Method for large-scale synthesis of tetrodotoxin
CN103342707B (en) For the preparation of the preparation method of A Sainaping intermediate
KR100226622B1 (en) Novel synthetic intermediate of muscone and the preparation thereof
KR19980065188A (en) New synthetic intermediates of moussecon and preparation method thereof
DE69910983T2 (en) SYNTHESIS OF CHIRAL BETA AMINO ACIDS
GB2036744A (en) Eburnane derivatives
KR102587674B1 (en) Process for Preparing Treprostinil
CN115594653B (en) Polysubstituted beta-alkenyl valerolactone compound, preparation method and application
US3833667A (en) Process for the preparation of 1,2-di-(o-or p-nitrophenyl)-ethanol
KR100256866B1 (en) Process for the preparation of l-muscone and d-muscone from d,l-muscone
Duddeck et al. Reactions of substituted 2-tert-butyladamantan-2-ols
WO2018213442A1 (en) Highly diastereoselective construction of the 4,5-spirocycle via palladium-catalyzed intramolecular alkenylation
CA2584349A1 (en) Process for the preparation of 2-methylspiro(1,3-oxathiolane-5,3') quiniclidine
RU2057140C1 (en) Method of synthesis of 6-oxa-8-isoanalogs of steroid estrogens
KR100449310B1 (en) preparation method of 2-deoxy-L-ribose
BE818471A (en) PROCESS FOR PREPARING 1-ARALKYL-4-AMINO-METHYLPIPERIDINE-4-OLS
KR101142052B1 (en) Method of preparing zanamivir
RU2371431C2 (en) Method producing quinopimaric acid
KR100841592B1 (en) Bezodiazole derivatives and process for preparing them
US8450487B2 (en) Process for the preparation of cis-2-methylspiro (1,3-oxathiolane 5-3′) quinuclidine
CN116143753A (en) NLRP3 inhibitor compounds

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120725

Year of fee payment: 14

FPAY Annual fee payment

Payment date: 20130729

Year of fee payment: 15

FPAY Annual fee payment

Payment date: 20140728

Year of fee payment: 16

LAPS Lapse due to unpaid annual fee